• br Other factors regulating DNA PKcs

  2021-04-10

  

  Other factors regulating DNA-PKcs Recent work in the field has also focused on factors that regulate NHEJ and NHEJ factors, in particular proteins that modulate DNA-PKcs. In this section we will highlight a number of factors which have been found to regulate DNA-PKcs. DNA-PKcs phosphorylation at

• We recently described the benzoxazin one

  2021-04-10

  

  We recently described the 1,3-benzoxazin-4-one analogue of LY294002 and showed it to have pan-PI3K and DNA-PK activity [2]. We have also reported on the activity of other family members, such as 3 which causes sensitization of lung cancer and colon cancer cells to radiation [11] and 4 (LTUSI122) as

• The Rev protein is a crucial regulator of TLS

  2021-04-10

  

  The Rev1 protein is a crucial regulator of TLS activity because of its structural function [10]; therefore, we focused on Rev1 to investigate how Dot1/Rad53 function impinges on TLS-dependent mutagenic bypass of MMS-induced lesions. In particular, we examined Rev1 localization to chromatin by immuno

• pri-724 High throughput screening HTS of

  2021-04-10

  

  High throughput screening (HTS) of the AstraZeneca pri-724 collection was conducted and identified oxadiazole amide () originating from a kinase directed screening library (although inactive against a panel of kinases). This compound had moderate potency as a DGAT-1 inhibitor (IC=0.52μM) and was sel

• Dorsomorphin Ligand independent constitutively active varian

  2021-04-10

  

  Ligand-independent, constitutively active variants have also been found in receptors with associated tyrosine kinases. In approximately 60% of patients harboring inflammatory hepatocellular adenomas (IHCAs), these adenomas have been caused by small in-frame deletions in the cytokine-binding domain o

• In our model CSF R

  2021-04-10

  

  In our model, CSF-1R blockade with PLX647 mainly targeted the more abundant MDSCs instead of macrophages, suggesting that the role of CSF-1 may be tumor model-dependent. Different tumor models, genetic backgrounds, or treatments may induce different growth factors or cytokines in the tumor microenvi

• Recently Zhao et al have been carried out

  2021-04-09

  

  Recently, Zhao et al. have been carried out a study to investigate the relationship between eNOS-4b/a polymorphism and the risk of LCPD in a Chinese population. Their results demonstrated that eNOS polymorphisms may be involved in the etiology of LCPD. However, the number of studies conducted to exa

• AICAR br Experimental procedures br Acknowledgments br Intro

  2021-04-09

  

  Experimental procedures Acknowledgments Introduction Receptor tyrosine kinases (RTKs) control many fundamental cellular processes, such as cell proliferation, differentiation, migration, and metabolism (Lemmon and Schlessinger, 2010). RTK activity is normally tightly controlled, and dysregu

• ELUXA HM EMSI is an

  2021-04-09

  

  ELUXA 1 (HM-EMSI-202) is an ongoing pivotal Phase II global clinical trial, designed to further investigate the efficacy and safety of Olmutinib in patients T790M-positive NSCLC with acquired resistance after first-line EGFR TKIs. Primary endpoint is ORR according to RECIST 1.1, while secondary endp

• Concerning family A GPCRs although it

  2021-04-09

  

  Concerning family A GPCRs, although it has been described that several receptors are able to operate as monomers (Arcemisbéhère et al., 2010; Bayburt et al., 2011; Chabre & le Maire, 2005; Ernst, Gramse, Kolbe, Hofmann, & Heck, 2007; Hanson et al., 2007; Kuszak et al., 2009; Whorton et al., 2007), e

• Besides chemopreventive effects against oxidative DNA damage

  2021-04-09

  

  Besides chemopreventive effects against oxidative DNA damage we evaluated the protective effects of the three Hypericum sp. and isolated compounds against alkylating DNA damage induced by MMS in HT29 cells. Human exposure to alkylating agents, from different sources, occurs in a continuous way and i

• In this study we further investigate how

  2021-04-08

  

  In this study, we further investigate how STAT3 integrate to the core regulatory circuit in ESC pluripotency and differentiation, and identify Mettl8 as a downstream target of STAT3 in mESCs. We discover the role of METTL8 as a negative regulator of JNK signaling in stem cells. Our results provide i

• br Chemistry The test compounds listed in

  2021-04-08

  

  Chemistry The test compounds listed in Table 1, Table 2, Table 3, Table 4, Table 5, were synthesized as outlined in Scheme 1, Scheme 2, Scheme 3, Scheme 4, Scheme 5. Synthesis of 2–5 is described in Scheme 1. N-Sulfonylation of the aniline 26 with benzenesulfonyl chloride afforded the sulfonamide

• In conclusion we designed novel E inhibitors based on

  2021-04-08

  

  In conclusion, we designed novel E1 inhibitors based on the three-dimensional structure of E1 in complex with ubiquitin. Following an enzymatic assay evaluating synthetic compounds , , and , we identified compound as a novel E1 inhibitor. Comparing the inhibitory activity of compound with and ,

• In vitro studies in NSCLC cell lines expressing

  2021-04-08

  

  In vitro studies in NSCLC cell lines expressing EGFR mutants (T790M mutation, exon 19 deletion E746-A750, L858R/T790M double mutation), demonstrated that Rociletinib potently inhibits proliferation in the mutant EGFR NSCLC BMS-345541 receptor with Growth inhibition (GI50) values ranging from 7 to 32

16460 records 692/1098 page Previous Next First page 上5页 691692693694695 下5页 Last page